Participants 0 102 6
Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy:
Participants 738 797 3
Eighty-four outpatient centers throughout the United States
Participants 799 950 6
PATIENTS A total of 1019 men and women aged 18 to 74 years with either type 1 or type 2 diabetes and a sensory polyneuropathy attributable to diabetes.
